Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine

This study is an observational study on the efficacy and safety of auto-HSCT in adult patients with Burkitt lymphoma, lymphoblastic lymphoma, and acute lymphoblastic leukemia who received TCCA conditioning regimen. The study plans to include 28 patients who received the TCCA regimen for pre-transplantation pretreatment before auto-HSCT. Maintenance treatment will be carried out after transplantation for 1 year to observe the efficacy and safety.

Trial Details

NCT ID
NCT06060782
Phase
PHASE1
Sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen
Locations (sample)
  • Zhuhai, Guangdong, China|22.27694,113.56778

Key Eligibility Criteria

  • 1\. Voluntarily sign the informed consent form, which must be signed by the patient himself.
  • 2\. ALL patients confirmed by bone marrow cell morphology, immunology, and genetics; 3. PH+ALL patients who achieve s3CMR (definition: achieve mole…
  • 6\. Patients receiving autologous hematopoietic stem cell transplantation (auto-HSCT); 7. Age ≥18 years and ≤65 years old, male or female; 8. Easte…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →